Receptor for advanced glycation endproduct modulators: A new therapeutic target in Alzheimer's disease

Expert Opinion on Investigational Drugs

Volumn 24, Issue 3, 2015, Pages 393-399

  Walker, Douglas ^a   Lue, Lih Fen ^a   Paul, Gaurav ^a   Patel, Amar ^a   Sabbagh, Marwan N ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

Alzheimer's disease; Clinical trials; Inflammation; Receptor for advanced glycation endproducts; amyloid

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR ANTAGONIST; AMYLOID BETA PROTEIN; LIPID; PF 4494700; ADVANCED GLYCATION END PRODUCT RECEPTOR; IMMUNOGLOBULIN RECEPTOR; LIGAND;

ALZHEIMER DISEASE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; NONHUMAN; PATHOGENESIS; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; DRUG DESIGN; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; DRUG DESIGN; HUMANS; LIGANDS; MOLECULAR TARGETED THERAPY; RECEPTORS, IMMUNOLOGIC;

EID: 84923016150     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2015.1001490     Document Type: Review

References (41)

1. Hebert LE, Weuve J, Scherr PA, et al. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 2013;80:1778-83
2. Beach TG. Alzheimer's disease and the quot;Valley Of Deathquot;: not enough guidance from human brain tissue? J Alzheimers Dis 2013;33(Suppl 1):S219-33
3. Bloom GS. Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol 2014;71:505-8
4. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984;120:885-90
5. Tanzi RE, Gusella JF, Watkins PC, et al. Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 1987;235:880-4
6. Sabbagh MN, Galasko D, Koo E, et al. Amyloid-beta and treatment opportunities for Alzheimer's disease. J Alzheimers Dis 2000;2:231-59
7. McGeer PL, McGeer EG. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol 2013;126:479-97
8. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010;362:329-44
9. Morgan D, Diamond DM, Gottschall PE, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000;408:982-5
10. Zotova E, Bharambe V, Cheaveau M, et al. Inflammatory components in human Alzheimer's disease and after active amyloid-beta42 immunization. Brain 2013;136:2677-96
11. Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370:322-33
12. Yan SD, Chen X, Fu J, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996;382:685-91
13. Takeuchi M, Yamagishi S. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. Curr Pharm Des 2008;14:973-8
14. Vicente MH, Outeiro TF. The sour side of neurodegenerative disorders: the effects of protein glycation. J Pathol 2010;221:13-25
15. Yan SD, Chen X, Schmidt AM, et al. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci USA 1994;91:7787-91
16. Neeper M, Schmidt AM, Brett J, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992;267:14998-5004
17. Schmidt AM, Yan SD, Wautier JL, et al. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999;84:489-97
18. Chen X, Walker DG, Schmidt AM, et al. RAGE: a potential target for Abetamediated cellular perturbation in Alzheimer's disease. Curr Mol Med 2007;7:735-42
19. Srikanth V, Maczurek A, Phan T, et al. Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiol Aging 2011;32:763-77
20. Nozaki I, Watanabe T, Kawaguchi M, et al. Reduced expression of endogenous secretory receptor for advanced glycation endproducts in hippocampal neurons of Alzheimer's disease brains. Arch Histol Cytol 2007;70:279-90
21. Zhang L, Postina R, Wang Y. Ectodomain shedding of the receptor for advanced glycation end products: a novel therapeutic target for Alzheimer's disease. Cell Mol Life Sci 2009;66:3923-35
22. Ghidoni R, Benussi L, Glionna M, et al. Decreased plasma levels of soluble receptor for advanced glycation end products in mild cognitive impairment. J Neural Transm 2008;115:1047-50
23. Lee EJ, Park JH. Receptor for advanced glycation endproducts (RAGE), its ligands, and soluble rage: potential biomarkers for diagnosis and therapeutic targets for human renal diseases. Genomics Inform 2013;11:224-9
24. Miller MC, Tavares R, Johanson CE, et al. Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease. Brain Res 2008;1230:273-80
25. Sasaki N, Toki S, Chowei H, et al. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res 2001;888:256-62
26. Lue LF, Walker DG, Brachova L, et al. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp Neurol 2001;171:29-45
27. Arancio O, Zhang HP, Chen X, et al. RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J 2004;23:4096-105
28. Fang F, Lue LF, Yan S, et al. RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/ memory in a mouse model of Alzheimer's disease. FASEB J 2010;24:1043-55
29. Origlia N, Criscuolo C, Arancio O, et al. RAGE inhibition in microglia prevents ischemia-dependent synaptic dysfunction in an amyloid-enriched environment. J Neurosci 2014;34:8749-60
30. Deane R, Du YS, Submamaryan RK, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003;9:907-13
31. Deane R, Wu Z, Sagare A, et al. LRP/ amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 2004;43:333-44
32. Donahue JE, Flaherty SL, Johanson CE, et al. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol 2006;112:405-15
33. Jeynes B, Provias J. Evidence for altered LRP/RAGE expression in Alzheimer lesion pathogenesis. Curr Alzheimer Res 2008;5:432-7
34. Deane R, Bell RD, Sagare A, et al. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets 2009;8:16-30
35. Deane R, Sagare A, Zlokovic BV. The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease. Curr Pharm Des 2008;14:1601-5
36. Sabbagh MN, Agro A, Bell J, et al. PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis Assoc Disord 2011;25:206-12
37. Deane R, Singh I, Sagare AP, et al. A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest 2012;122:1377-92
38. Carnevale D, Mascio G, D'Andrea I, et al. Hypertension induces brain betaamyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature. Hypertension 2012;60:188-97
39. Burstein AH, Grimes I, Galasko DR, et al. Effect of TTP488 in patients with mild to moderate Alzheimer's disease. BMC Neurol 2014;14:12
40. Galasko D, Bell J, Mancuso J, et al. for the ADCS. Clinical trial of an inhibitor of RAGE-Abeta interactions in Alzheimer's disease. Neurology 2014;82(17):1536-42
41. Castellani RJ, Smith MA. Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is 'too big to fail'. J Pathol 2011;224(2):147-52